The Forgotten Checkpoints
Time to shine the light on alternative checkpoint targets
The annual meeting of the American Society of Clinical Oncology (ASCO) is always a great place to find hidden gems or off the radar molecules.
This year we’re going to highlight progress on two closely related IO targets to illustrate how perceptions may change from the pummelling several of them received at SITC a couple of years ago.
There’s always a danger in writing off initial very early and immature data based on a limited number of allcomers in relapsed/refractory solid tumour trials, where the focus is more on dose finding and safety signals before proceeding to more clearly defined tumour types in expansion cohorts.
Three or four years on, how are these hidden niches doing and what can we learn from the data to be presented?
To find out, we took a dive unto the breach…
To read our latest discussion on early oncology new product development plus commentary and analysis BSB subscribers can log-in or you can click to access the content.
This content is restricted to subscribers
In this latest article, we highlight ten areas within the niche and include an array of companies, both big and small, across Pharma and Biotechs.